NEW YORK (GenomeWeb News) – Bio-Reference Laboratories today said that it is making an equity investment of up to $6 million in molecular diagnostics firm InCellDx.

Under the terms of the agreement, Bio-Reference will purchase up to $6 million in shares of InCellDex's preferred stock and warrants representing between 20 percent and 25 percent of InCellDx, depending on dilution resulting from the exercise of outstanding options. The $6 million investment will be comprised of $4 million in cash and $2 million by promissory note.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.